While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of ...

Brian Jeansonne and his wife Kristy open up about how they've used TikTok to find community after he was diagnosed with ALS ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

Voyager Therapeutics (VYGR) has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 amyotrophic ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...